Abstract
Arterial hypertension is one of the most important risk factors for cardiovascular disease. Angiotensin-1- receptor blockers (ARB) are a class of drugs that potently inhibit the vasoconstriction and other vascular effects of angiotensin including proliferation of vascular smooth muscle cells by selective binding to the AT1-receptor. The present review summarizes the most relevant experimental and clinical data on this new class of drugs. ARBs inhibit effects of angiotensin II on the vasoconstriction and proliferation of vascular smooth muscle cells, reduce sympathetic activation, increase bradykinin dependent vasodilator effects and increase Ang(1-7), a metabolite of angiotensin, which has vascular protective properties. ARBs also interfere with the interactions of the renin-angiotensinsystem with both the endothelin-system and the sympathetic nervous system. Under in vivo conditions in men, ARBs have a potent antihypertensive effect and have fewer side effects than any other class of antihypertensives. The available ARBs differ regarding their metabolism, plasma half-life and trough-to-peakratio. Several clinical trials have proven that ARBs are safe and effective in reducing morbidity and mortality in hypertension, diabetic and non-diabetic renal disease, acute myocardial infarction as well as systolic and diastolic heart failure. Importantly, protection from cerebrovascular disease and from cardiovascular disease after stroke is an emerging property of ARBs and is likely to be partially independent from the blood-pressure lowering effects. ARBs, similarly to ACE-inhibitors and in contrast to diuretics, have proven to reduce the incidence on new-onset diabetes, which is likely to be clinically relevant in the chronic treatment of hypertension and cardiac disease. Furthermore, ARBs reduce the incidence of atrial fibrillation in hypertensive patients. The reasons for these beneficial effects of ARBs are discussed and include improvement of endothelial function and renal hemodynamics, reduction in central nervous sympathetic tone, interaction with the endothelin-system and potent reduction of left ventricular hypertrophy. Thus, ARBs are an important new, well tolerated class of cardiovascular drugs, which reduce morbidity and mortality from cardiac, renal and cerebrovascular disease.
Keywords: stroke, antiproliferative, antihypertensive, cerebrovascular events, Diabetic nephropathy, fibrillation
Current Drug Therapy
Title: Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Volume: 1 Issue: 1
Author(s): Rene R. Wenzel
Affiliation:
Keywords: stroke, antiproliferative, antihypertensive, cerebrovascular events, Diabetic nephropathy, fibrillation
Abstract: Arterial hypertension is one of the most important risk factors for cardiovascular disease. Angiotensin-1- receptor blockers (ARB) are a class of drugs that potently inhibit the vasoconstriction and other vascular effects of angiotensin including proliferation of vascular smooth muscle cells by selective binding to the AT1-receptor. The present review summarizes the most relevant experimental and clinical data on this new class of drugs. ARBs inhibit effects of angiotensin II on the vasoconstriction and proliferation of vascular smooth muscle cells, reduce sympathetic activation, increase bradykinin dependent vasodilator effects and increase Ang(1-7), a metabolite of angiotensin, which has vascular protective properties. ARBs also interfere with the interactions of the renin-angiotensinsystem with both the endothelin-system and the sympathetic nervous system. Under in vivo conditions in men, ARBs have a potent antihypertensive effect and have fewer side effects than any other class of antihypertensives. The available ARBs differ regarding their metabolism, plasma half-life and trough-to-peakratio. Several clinical trials have proven that ARBs are safe and effective in reducing morbidity and mortality in hypertension, diabetic and non-diabetic renal disease, acute myocardial infarction as well as systolic and diastolic heart failure. Importantly, protection from cerebrovascular disease and from cardiovascular disease after stroke is an emerging property of ARBs and is likely to be partially independent from the blood-pressure lowering effects. ARBs, similarly to ACE-inhibitors and in contrast to diuretics, have proven to reduce the incidence on new-onset diabetes, which is likely to be clinically relevant in the chronic treatment of hypertension and cardiac disease. Furthermore, ARBs reduce the incidence of atrial fibrillation in hypertensive patients. The reasons for these beneficial effects of ARBs are discussed and include improvement of endothelial function and renal hemodynamics, reduction in central nervous sympathetic tone, interaction with the endothelin-system and potent reduction of left ventricular hypertrophy. Thus, ARBs are an important new, well tolerated class of cardiovascular drugs, which reduce morbidity and mortality from cardiac, renal and cerebrovascular disease.
Export Options
About this article
Cite this article as:
Wenzel R. Rene, Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease, Current Drug Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157488506775268443
DOI https://dx.doi.org/10.2174/157488506775268443 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Current Vascular Pharmacology Circulating ACE2 in Cardiovascular and Kidney Diseases
Current Medicinal Chemistry Preface
Current Cardiology Reviews Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative Stress
Current Pharmaceutical Biotechnology Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Nanotechnology and Drug Delivery: Getting There is Only Half of the Challenge! (Commentary)
CNS & Neurological Disorders - Drug Targets Encephalopathy: A Vicious Cascade Following Forebrain Ischemia and Hypoxia
Central Nervous System Agents in Medicinal Chemistry Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews New Technologies in Male Contraception
Current Women`s Health Reviews Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Pharmacological Characterisation of Spider Antimicrobial Peptides
Protein & Peptide Letters Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets The Chemistry of Bioactive Diterpenes
Current Organic Chemistry Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design